TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair